TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes
June 08, 2015 at 16:30 PM EDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating ...